+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Management Strategies in Antithrombotic Therapy

  • ID: 2170752
  • Book
  • 366 Pages
  • John Wiley and Sons Ltd
1 of 3
Intravascular thrombus formation remains one of the most significant problems in cardiovascular medicine and a major risk in many interventional procedures. Today, clinicians have a wide choice of antithrombotic and anticoagulant agents available, including aspirin, thienopyridines, platelet glycoprotein IIb/IIIa inhibitors, low molecular weight heparins, thrombin inhibitors, and fibrinolytic agents. Though effective, all of these agents possess limitations, the most common being an increased risk of bleeding. Implementing the most appropriate, and safe, anticoagulation therapy across the spectrum of cardiovascular disease, in the presence of a wide range of other risk factors, remains a challenge.

Incorporating the most up to date evidence–based review of each class of agents, this book acquaints readers with the data behind the commonly used anti–thrombotic agents and will assist them in formulating a sound, therapeutic strategy appropriate for each patient.

Note: Product cover images may vary from those shown
2 of 3
Abbreviations and Acronyms.


Chapter 1. Thrombosis and Antithrombotics in Vascular Disease.

1.1 The Burden of Thrombosis.

1.2 Essential components of thrombosis.

1.3 Thrombosis in the acute ischemic syndromes.

1.4 Venous thromboembolic disease.

1.5 The ideal antithrombotic agent.

Chapter 2. Aspirin.

2.1 Introduction.

2.2 Pharmacology.

2.3 Clinical uses of aspirin.

2.4 Conclusions.

Chapter 3. Thienopyridines Ticlopidine and Clopidogrel.

3.1 Introduction.

3.2 Pharmacology.

3.3 Clinical uses of the thienopyridines.

3.4 Conclusions.

Chapter 4. Platelet Glycoprotein IIb/IIIa Inhibitors.

4.1 Introduction.

4.2 GP IIb/IIIa receptor inhibitors.

4.3 GP IIb/IIIa inhibitors during percutaneous coronary revascularization.

4.4 GP IIb/IIIa inhibitors in the management of non–st–elevation ACS.

4.5 GP IIb/IIIa inhibitors in the management of acute STEMI.

4.6 Safety of GP IIb/IIIa inhibitors.

4.7 Summary.

Chapter 5. Unfractionated Heparin.

5.1 Introduction.

5.2 Pharmacology.

5.3 Clinical uses of UH.

5.4 Clinical considerations.

5.5 Conclusions.

Chapter 6. Low–Molecular–Weight Heparins.

6.1 Introduction.

6.2 Comparisons between UH and LMWH.

6.3 Clinical uses of LMWH.

6.4 Conclusions.

Chapter 7 Direct Thrombin Inhibitors.

7.1 Introduction.

7.2 Overview of DTIs.

7.3 Clinical uses of DTIs.

7.4 Summary.

Chapter 8. Fibrinolytic agents.

8.1 Introduction.

8.2 Fibrinolytic agents for STEMI.

8.3 Fibrinolytics for VTE.

8.4 Conclusions.

Chapter 9. Acute ST–Segment–Elevation Myocardial Infarction.

9.1 Introduction.

9.2 Definitive therapy.

9.3 Adjunctive therapy.

9.4 Recommendations.

9.5 Conclusions.

Chapter 10. Acute Coronary Syndromes: Unstable Angina /Non–ST–Segment–Elevation Myocardial Infarction (NSTE ACS).

10.1 Introduction.

10.2 Antithrombotic approach to patients with ACS/NSTEMI.

10.3 Early invasive versus early conservative strategies.

10.4 Recommendations.

10.5 Conclusions.

Chapter 11 Anticoagulation Strategies for Patients Undergoing Percutaneous Coronary Intervention.

11.1 Introduction.

11.2 Antiplatelet therapy.

11.3 Antithrombotic therapy.

11.4 Special populations.

11.5 Recommendations.

11.6 Conclusions.

Chapter 12 Venous Thromboembolic Disease.

12.1 Introduction.

12.2 Risk of VTE.

12.3 Prevention of VTE.

12.4 Treatment of VTE.

12.5 Conclusions.

Chapter 13. Heparin–Induced Thrombocytopenia.

13.1 Introduction.

13.2 Incidence.

13.3 Pathogenesis.

13.4 Clinical manifestations.

13.5 Diagnosis.

13.6 Prevention.

13.7 Treatment.

13.8 Conclusions.


Note: Product cover images may vary from those shown
3 of 3


4 of 3
Arman Askari
Michael Lincoff
Adrian Messerli
Note: Product cover images may vary from those shown